Absci Corp
ABSI2.925USD
+0.025+0.86%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
373.06MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Absci Corp Unternehmen
Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.
Unternehmensinformationen
BörsenkürzelABSI
Name des UnternehmensAbsci Corp
IPO-datumJul 22, 2021
CEOMr. Sean Mcclain
Anzahl der mitarbeiter156
WertpapierartOrdinary Share
GeschäftsjahresendeJul 22
Addresse18105 Se Mill Plain Blvd
StadtVANCOUVER
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl98683
Telefon13609491041
Websitehttps://www.absci.com/
BörsenkürzelABSI
IPO-datumJul 22, 2021
CEOMr. Sean Mcclain
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.73M
+1.38%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
133.62K
-3.74%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
131.48K
+61.36%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Ms. Mary T. Szela
Ms. Mary T. Szela
Director
Director
--
--
Mr. Frans Van Houten
Mr. Frans Van Houten
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Independent Director
Independent Director
--
--
Dr. Joseph Sirosh, Ph.D.
Dr. Joseph Sirosh, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.73M
+1.38%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
133.62K
-3.74%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
131.48K
+61.36%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Jun 24
Aktualisiert: Tue, Jun 24
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
12.75%
ARK Investment Management LLC
6.97%
McClain (Sean)
6.05%
Redmile Group, LLC
5.72%
The Vanguard Group, Inc.
4.47%
Other
64.04%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
12.75%
ARK Investment Management LLC
6.97%
McClain (Sean)
6.05%
Redmile Group, LLC
5.72%
The Vanguard Group, Inc.
4.47%
Other
64.04%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
36.08%
Investment Advisor/Hedge Fund
18.18%
Individual Investor
6.46%
Hedge Fund
4.02%
Corporation
3.29%
Research Firm
1.79%
Bank and Trust
0.24%
Venture Capital
0.21%
Pension Fund
0.02%
Other
29.72%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
307
100.37M
69.60%
-3.07M
2025Q1
316
100.15M
78.58%
-546.74K
2024Q4
298
92.04M
80.13%
-8.74M
2024Q3
280
90.06M
79.27%
-8.98M
2024Q2
257
91.26M
83.61%
+4.72M
2024Q1
236
84.09M
77.41%
+14.50M
2023Q4
202
58.01M
62.41%
-6.63M
2023Q3
196
57.87M
62.40%
-7.67M
2023Q2
191
58.28M
63.02%
-12.48M
2023Q1
181
65.82M
71.20%
-6.10M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
18.39M
14.41%
+4.87M
+36.07%
Mar 31, 2025
ARK Investment Management LLC
10.96M
8.59%
+2.69M
+32.53%
Mar 31, 2025
McClain (Sean)
8.73M
6.84%
+119.00K
+1.38%
Mar 31, 2025
Redmile Group, LLC
8.25M
6.47%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
4.69M
3.67%
-86.40K
-1.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.25M
4.9%
+325.67K
+5.50%
Mar 31, 2025
Phoenix Ventures Partners II LP.
4.75M
3.72%
-4.61M
-49.28%
Mar 31, 2025
Fred Alger Management, LLC
4.29M
3.37%
-2.21M
-33.99%
Mar 31, 2025
Columbia Wanger Asset Management, LLC
2.40M
1.88%
--
--
Mar 31, 2025
MFS Investment Management
2.31M
1.81%
+20.59K
+0.90%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ARK Genomic Revolution ETF
2.39%
WisdomTree BioRevolution Fund
0.95%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil2.39%
WisdomTree BioRevolution Fund
Anteil0.95%
iShares Micro-Cap ETF
Anteil0.06%
Invesco Nasdaq Biotechnology ETF
Anteil0.04%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
iShares Biotechnology ETF
Anteil0.03%
Proshares Ultra Russell 2000
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
iShares Russell 2000 Growth ETF
Anteil0.01%
Schwab U.S. Small-Cap ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
